<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-Z5JVRIXM</identifier><date>2022</date><creator>Amir, Eitan</creator><creator>Grčar-Kuzmanov, Biljana</creator><creator>Jerič Horvat, Valentina</creator><creator>Langerholc, Erik</creator><creator>Novaković, Srdjan</creator><creator>Pohar Perme, Maja</creator><creator>Ratoša, Ivica</creator><creator>Ribnikar, Domen</creator><creator>Šeruga, Boštjan</creator><creator>Veitch, Zachary</creator><relation>documents/doc/Z/URN_NBN_SI_doc-Z5JVRIXM_001.pdf</relation><relation>documents/doc/Z/URN_NBN_SI_doc-Z5JVRIXM_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 115-116</format><identifier identifier_type="COBISSID_HOST">139386371</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-Z5JVRIXM</identifier><language>slv</language><publisher publisher_location="Ljubljana">Kancerološko združenje Slovenskega zdravniškega društva</publisher><publisher publisher_location="Ljubljana">Onkološki inštitut</publisher><source>34. onkološki vikend</source><rights>InC</rights><subject language_type_id="slv">kemoterapija</subject><subject language_type_id="slv">onkologija</subject><subject language_type_id="slv">rak dojke</subject><title>Pomen PIK3CA aktivirajočih mutacij za izid bolezni pri bolnicah z invazivnim lobularnim karcinomom dojke, zdravljenih z dopolnilno endokrino terapijo</title></Record>